CXCR4 Inhibitor in Combination With Pembrolizumab/Chemotherapy for Metastatic Pancreatic Cancer – The ASCO Post

By The ASCO Post StaffPosted: 12/16/2019 9:06:00 AM Last Updated: 12/20/2019 1:45:34 PM When the CXCR4 inhibitor BL-8040 was combined with the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab plus chemotherapy in the second-line setting, the regimen showed promising antitumor…

Read the full article here

Related Articles